Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

-- This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting -- -- FDA granted the applications Priority [...]